Exelixis Eyes Q1 Zanza Data as It Plans Beyond CABO

Exelixis logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Exelixis expects top-line results from the STELLAR-304 Zanza trial in the first quarter, following a year-end clinical cutoff and database preparation. The study’s blinded data do not yet support conclusions, and the company says results will determine whether response and survival outcomes are meaningful.
  • The company is preparing to expand beyond its CABO franchise, with seven pivotal Zanza studies that Peters said could potentially replace CABO and support growth; Exelixis is also considering a second wave of studies and other development opportunities.
  • Exelixis aims to keep annual R&D spending near $1 billion while balancing internal research, external deals and share buybacks. Peters said revenue growth with a flat expense base could boost earnings and give the company more investment flexibility.
  • MarketBeat previews top five stocks to own in December.

Exelixis NASDAQ: EXEL is preparing for a transition from a company built around its CABO franchise to one with multiple products, as it advances seven pivotal studies of Zanza and weighs additional development opportunities, Chief Strategy Officer Andrew Peters said at the Jefferies London Healthcare Conference.

Peters said the company is balancing internal research, external deals and share buybacks while aiming to keep annual research and development spending at around $1 billion. He said revenue growth alongside a flat expense line could accelerate earnings and give Exelixis flexibility to invest across those priorities.

“We run Exelixis like a business and not a biotech,” Peters said, adding that execution and prioritization are central to the company’s strategy.

STELLAR-304 Data Expected in First Quarter

One of the company’s near-term milestones is the STELLAR-304 study of Zanza in non-clear cell renal cell carcinoma. Peters said trial events are occurring more slowly than Exelixis modeled, but cautioned against drawing conclusions from blinded data.

Based on what the company is seeing, Exelixis expects a clinical cutoff around year-end, followed by database locking and cleaning, with top-line results sometime in the first quarter, Peters said.

He said he did not yet know what the initial press release would disclose. An interim overall survival analysis will be conducted when the number of progression-free survival events triggers the primary analysis, although he said he was unsure how mature those survival data would be.

Exelixis hopes to see meaningful response-rate, progression-free survival and overall survival results, Peters said, while emphasizing that the outcome remains dependent on the data. He described non-clear cell disease as the smallest of the indications in the ongoing Zanza program.

Zanza Development Builds on CABO Experience

Peters said Exelixis is using experience and data from CABO, alongside early Zanza data, to guide its development plans. He cited bladder cancer as an area of interest, noting that changes in the treatment landscape have affected how the company evaluates opportunities.

The company designed Zanza to retain a kinase inhibition profile similar to CABO’s while shortening its half-life, Peters said. He said the shorter half-life could make dose holds and symptom management more straightforward, particularly in combinations where multiple drugs may have overlapping adverse effects.

Peters also pointed to differences in tissue distribution and said the company has observed differences in hand-foot syndrome, also known as PPE. The conference host noted that Zanza and CABO are not being directly compared in the trials.

Asked whether Zanza’s profile could translate into stronger survival outcomes, Peters said large randomized survival studies are needed to answer that question. The relationship between response, progression-free survival and overall survival may also vary by indication, he said.

Next Wave and Capital Priorities

Exelixis is considering a second wave of Zanza studies, though Peters did not provide a timeline or announce specific trials. He said the company’s seven pivotal studies collectively have the potential to replace CABO and support growth, while a further wave could expand the potential market.

In frontline metastatic renal cell carcinoma, Peters said the failure of LITESPARK-012 had opened opportunities for Exelixis to think more broadly about development. He said the company is interested in mechanisms distinct from doubling down on the VEGF pathway and described collaborations as a model Exelixis favors.

Any new investment must compete for resources with the company’s other plans, Peters said. Exelixis also retains the option to pursue external opportunities using its balance sheet, he added.

About Exelixis (NASDAQ:EXEL)

Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Exelixis Right Now?

Before you consider Exelixis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.

While Exelixis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines